Teng Xue, Ying Cui, Ying Kan, Guanyun Wang, Jigang Yang
{"title":"Value of multi-parameter <sup>123</sup>I-MIBG scintigraphy in the differential diagnosis of Parkinson's disease.","authors":"Teng Xue, Ying Cui, Ying Kan, Guanyun Wang, Jigang Yang","doi":"10.1186/s13550-025-01197-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><sup>123</sup>I-MIBG scintigraphy plays a significant role in diagnosing Parkinson's disease (PD), with most studies primarily targeting cardiac uptake and relying on traditional ratio-based parameters for assessment. However, due to variations in scanning conditions and image processing methodologies, the clinical utility of different parameters remains a subject of debate. This study aims to evaluate the diagnostic accuracy of multi-parameter <sup>123</sup>I-3-Iodobenzylguanidine (MIBG) scintigraphy and to identify the most reliable metrics for distinguishing PD from Parkinson-plus syndromes.</p><p><strong>Result: </strong>We recruited 56 PD patients and 44 non-PD controls, who underwent <sup>123</sup>I-MIBG scintigraphy and clinical evaluation. MIBG uptake and washout rates (WR) for the heart, salivary glands, and thyroid were assessed, with semi-quantitative methods used to calculate heart-to-mediastinum (H/M) and gland-to-background (P/B, S/B, T/B) ratios. Diagnostic efficacy was evaluated using receiver operating characteristic (ROC) curves. The H/M ratio and cardiac WR parameters scintigraphy exhibited excellent diagnostic efficacy for PD and PPS. The 4 h H/M ratio showed superior diagnostic performance with an area under the ROC curve (AUC) of 0.980. Background and time decay correction improved cardiac WR diagnostic performance (AUC = 0.963). Although P/B, S/B, and T/B ratios showed no significant differences for differential diagnosis, the WR values of the parotid and thyroid glands exhibited moderate diagnostic efficacy with AUCs of 0.648 and 0.638, respectively.</p><p><strong>Conclusion: </strong>The heart H/M ratio and cardiac WR in <sup>123</sup>I-MIBG scintigraphy show high diagnostic efficacy for both diagnosing and differentiating PD. Including cardiac WR in routine assessments is recommended. The diagnostic potential of WR in the parotid and thyroid glands also holds promise for PD diagnosis. Incorporating these parameters could enhance the accuracy of PD diagnosis, particularly in clinical scenarios where concurrent cardiac disease may confound the diagnosis.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"7"},"PeriodicalIF":3.1000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775374/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-025-01197-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: 123I-MIBG scintigraphy plays a significant role in diagnosing Parkinson's disease (PD), with most studies primarily targeting cardiac uptake and relying on traditional ratio-based parameters for assessment. However, due to variations in scanning conditions and image processing methodologies, the clinical utility of different parameters remains a subject of debate. This study aims to evaluate the diagnostic accuracy of multi-parameter 123I-3-Iodobenzylguanidine (MIBG) scintigraphy and to identify the most reliable metrics for distinguishing PD from Parkinson-plus syndromes.
Result: We recruited 56 PD patients and 44 non-PD controls, who underwent 123I-MIBG scintigraphy and clinical evaluation. MIBG uptake and washout rates (WR) for the heart, salivary glands, and thyroid were assessed, with semi-quantitative methods used to calculate heart-to-mediastinum (H/M) and gland-to-background (P/B, S/B, T/B) ratios. Diagnostic efficacy was evaluated using receiver operating characteristic (ROC) curves. The H/M ratio and cardiac WR parameters scintigraphy exhibited excellent diagnostic efficacy for PD and PPS. The 4 h H/M ratio showed superior diagnostic performance with an area under the ROC curve (AUC) of 0.980. Background and time decay correction improved cardiac WR diagnostic performance (AUC = 0.963). Although P/B, S/B, and T/B ratios showed no significant differences for differential diagnosis, the WR values of the parotid and thyroid glands exhibited moderate diagnostic efficacy with AUCs of 0.648 and 0.638, respectively.
Conclusion: The heart H/M ratio and cardiac WR in 123I-MIBG scintigraphy show high diagnostic efficacy for both diagnosing and differentiating PD. Including cardiac WR in routine assessments is recommended. The diagnostic potential of WR in the parotid and thyroid glands also holds promise for PD diagnosis. Incorporating these parameters could enhance the accuracy of PD diagnosis, particularly in clinical scenarios where concurrent cardiac disease may confound the diagnosis.
EJNMMI ResearchRADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-
CiteScore
5.90
自引率
3.10%
发文量
72
审稿时长
13 weeks
期刊介绍:
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.
The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.